1
|
Molecular Insights into Potential Contributions of Natural Polyphenols to Lung Cancer Treatment. Cancers (Basel) 2019; 11:cancers11101565. [PMID: 31618955 PMCID: PMC6826534 DOI: 10.3390/cancers11101565] [Citation(s) in RCA: 17] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/16/2019] [Revised: 10/13/2019] [Accepted: 10/13/2019] [Indexed: 12/12/2022] Open
Abstract
Naturally occurring polyphenols are believed to have beneficial effects in the prevention and treatment of a myriad of disorders due to their anti-inflammatory, antioxidant, antineoplastic, cytotoxic, and immunomodulatory activities documented in a large body of literature. In the era of molecular medicine and targeted therapy, there is a growing interest in characterizing the molecular mechanisms by which polyphenol compounds interact with multiple protein targets and signaling pathways that regulate key cellular processes under both normal and pathological conditions. Numerous studies suggest that natural polyphenols have chemopreventive and/or chemotherapeutic properties against different types of cancer by acting through different molecular mechanisms. The present review summarizes recent preclinical studies on the applications of bioactive polyphenols in lung cancer therapy, with an emphasis on the molecular mechanisms that underlie the therapeutic effects of major polyphenols on lung cancer. We also discuss the potential of the polyphenol-based combination therapy as an attractive therapeutic strategy against lung cancer.
Collapse
|
2
|
Pircher A, Jöhrer K, Kocher F, Steiner N, Graziadei I, Heidegger I, Pichler R, Leonhartsberger N, Kremser C, Kern J, Untergasser G, Gunsilius E, Hilbe W. Biomarkers of evasive resistance predict disease progression in cancer patients treated with antiangiogenic therapies. Oncotarget 2018; 7:20109-23. [PMID: 26956051 PMCID: PMC4991441 DOI: 10.18632/oncotarget.7915] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/02/2015] [Accepted: 02/16/2016] [Indexed: 01/03/2023] Open
Abstract
Numerous antiangiogenic agents are approved for the treatment of oncological diseases. However, almost all patients develop evasive resistance mechanisms against antiangiogenic therapies. Currently no predictive biomarker for therapy resistance or response has been established. Therefore, the aim of our study was to identify biomarkers predicting the development of therapy resistance in patients with hepatocellular cancer (n = 11), renal cell cancer (n = 7) and non-small cell lung cancer (n = 2). Thereby we measured levels of angiogenic growth factors, tumor perfusion, circulating endothelial cells (CEC), circulating endothelial progenitor cells (CEP) and tumor endothelial markers (TEM) in patients during the course of therapy with antiangiogenic agents, and correlated them with the time to antiangiogenic progression (aTTP). Importantly, at disease progression, we observed an increase of proangiogenic factors, upregulation of CEC/CEP levels and downregulation of TEMs, such as Robo4 and endothelial cell-specific chemotaxis regulator (ECSCR), reflecting the formation of torturous tumor vessels. Increased TEM expression levels tended to correlate with prolonged aTTP (ECSCR high = 275 days vs. ECSCR low = 92.5 days; p = 0.07 and for Robo4 high = 387 days vs. Robo4 low = 90.0 days; p = 0.08). This indicates that loss of vascular stabilization factors aggravates the development of antiangiogenic resistance. Thus, our observations confirm that CEP/CEC populations, proangiogenic cytokines and TEMs contribute to evasive resistance in antiangiogenic treated patients. Higher TEM expression during disease progression may have clinical and pathophysiological implications, however, validation of our results is warranted for further biomarker development.
Collapse
Affiliation(s)
- Andreas Pircher
- Department of Internal Medicine V, Hematology and Oncology, Medical University Innsbruck, Innsbruck, Austria
| | - Karin Jöhrer
- Tyrolean Cancer Research Institute, Innsbruck, Austria
| | - Florian Kocher
- Department of Internal Medicine V, Hematology and Oncology, Medical University Innsbruck, Innsbruck, Austria.,Tyrolean Cancer Research Institute, Innsbruck, Austria
| | - Normann Steiner
- Department of Internal Medicine V, Hematology and Oncology, Medical University Innsbruck, Innsbruck, Austria
| | - Ivo Graziadei
- Department of Internal Medicine II, Gastroenterology and Hepatology, Medical University Innsbruck, Innsbruck, Austria
| | - Isabel Heidegger
- Department of Urology, Medical University Innsbruck, Innsbruck, Austria
| | - Renate Pichler
- Department of Urology, Medical University Innsbruck, Innsbruck, Austria
| | | | - Christian Kremser
- Department of Radiology, Medical University Innsbruck, Innsbruck, Austria
| | - Johann Kern
- Department of Internal Medicine V, Hematology and Oncology, Medical University Innsbruck, Innsbruck, Austria
| | - Gerold Untergasser
- Department of Internal Medicine V, Hematology and Oncology, Medical University Innsbruck, Innsbruck, Austria
| | - Eberhard Gunsilius
- Department of Internal Medicine V, Hematology and Oncology, Medical University Innsbruck, Innsbruck, Austria
| | - Wolfgang Hilbe
- Department of Internal Medicine V, Hematology and Oncology, Medical University Innsbruck, Innsbruck, Austria.,Department of Oncology, Hematology and Palliative Care Wilhelminenspital, Vienna, Austria
| |
Collapse
|
3
|
Synergies of Targeting Tumor Angiogenesis and Immune Checkpoints in Non-Small Cell Lung Cancer and Renal Cell Cancer: From Basic Concepts to Clinical Reality. Int J Mol Sci 2017; 18:ijms18112291. [PMID: 29088109 PMCID: PMC5713261 DOI: 10.3390/ijms18112291] [Citation(s) in RCA: 31] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/08/2017] [Revised: 10/26/2017] [Accepted: 10/29/2017] [Indexed: 02/08/2023] Open
Abstract
In recent years, considerable advances concerning therapeutic strategies in patients with metastatic cancer have been achieved. Particularly in renal cell cancer (RCC) and advanced stage non-small cell lung cancer (NSCLC), immune-activating and antiangiogenic (AA) drugs (i.e., checkpoint antibodies and vascular endothelial growth factor (VEGF)/VEGF receptors (VEGFR) targeting compounds, respectively) have been successfully developed. As immune-effector cells have to enter the tumor, it is tempting to speculate that the combination of immunotherapy with AA treatment may induce synergistic effects. In this short review, we explore the theoretical background and the therapeutic potential of this novel treatment option for patients with advanced RCC or NSCLC. We discuss the growing body of evidence that pro-angiogenic factors negatively modulate the T-cell-mediated immune response and examine the preclinical evidence for testing combined immune-activating and AA therapy concepts in clinical practice. Particular attention will also be paid to potential novel treatment-related adverse events induced by combination treatment.
Collapse
|
4
|
Zamay GS, Ivanchenko TI, Zamay TN, Grigorieva VL, Glazyrin YE, Kolovskaya OS, Garanzha IV, Barinov AA, Krat AV, Mironov GG, Gargaun A, Veprintsev DV, Bekuzarov SS, Kirichenko AK, Zukov RA, Petrova MM, Modestov AA, Berezovski MV, Zamay AS. DNA Aptamers for the Characterization of Histological Structure of Lung Adenocarcinoma. MOLECULAR THERAPY. NUCLEIC ACIDS 2017; 6:150-162. [PMID: 28325282 PMCID: PMC5363495 DOI: 10.1016/j.omtn.2016.12.004] [Citation(s) in RCA: 23] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 04/04/2016] [Revised: 12/05/2016] [Accepted: 12/05/2016] [Indexed: 12/31/2022]
Abstract
Nucleic acid aptamers are becoming popular as molecular probes for identification and imaging pathology and, at the same time, as a convenient platform for targeted therapy. Recent studies have shown that aptamers may be effectively used for tumor characterization and as commercially available monoclonal antibodies. Here we present three DNA aptamers binding to whole transformed lung cancer tissues, including tumor cells, connective tissues, and blood vessels. Protein targets have been revealed using affinity purification followed by mass spectrometry analyses, and they have been validated using a panel of correspondent antibodies and 3D imaging of tumor tissues. Each of the proteins targeted by the aptamers is involved in cancer progression and most of them are crucial for lung adenocarcinoma. We propose the use of these aptamers in aptahistochemistry for the characterization of the histological structure of lung adenocarcinoma. The value of the presented aptamers is their application together or separately for indicating the spread of neoplastic transformation, for complex differential diagnostics, and for targeted therapy of the tumor itself as well as all transformed structures of the adjacent tissues. Moreover, it has been demonstrated that these aptamers could be used for intraoperative tumor visualization and margin assessment.
Collapse
Affiliation(s)
- Galina S Zamay
- Laboratory for Biomolecular and Medical Technologies, Krasnoyarsk State Medical University, Krasnoyarsk 660022, Russia; Institute of Chemistry and Chemical Technology of the Siberian Branch of the Russian Academy of Science, Krasnoyarsk 660036, Russia
| | - Tatiana I Ivanchenko
- Laboratory for Biomolecular and Medical Technologies, Krasnoyarsk State Medical University, Krasnoyarsk 660022, Russia
| | - Tatiana N Zamay
- Laboratory for Biomolecular and Medical Technologies, Krasnoyarsk State Medical University, Krasnoyarsk 660022, Russia
| | - Valentina L Grigorieva
- Laboratory for Biomolecular and Medical Technologies, Krasnoyarsk State Medical University, Krasnoyarsk 660022, Russia
| | - Yury E Glazyrin
- Laboratory for Biomolecular and Medical Technologies, Krasnoyarsk State Medical University, Krasnoyarsk 660022, Russia
| | - Olga S Kolovskaya
- Laboratory for Biomolecular and Medical Technologies, Krasnoyarsk State Medical University, Krasnoyarsk 660022, Russia; Institute of Chemistry and Chemical Technology of the Siberian Branch of the Russian Academy of Science, Krasnoyarsk 660036, Russia
| | - Irina V Garanzha
- Laboratory for Biomolecular and Medical Technologies, Krasnoyarsk State Medical University, Krasnoyarsk 660022, Russia; Institute of Chemistry and Chemical Technology of the Siberian Branch of the Russian Academy of Science, Krasnoyarsk 660036, Russia
| | | | - Alexey V Krat
- Krasnoyarsk Regional Clinical Cancer Center, Krasnoyarsk 660022, Russia
| | - Gleb G Mironov
- Department of Chemistry and Biomolecular Sciences, University of Ottawa, Ottawa, ON K1N 6N5, Canada
| | - Ana Gargaun
- Department of Chemistry and Biomolecular Sciences, University of Ottawa, Ottawa, ON K1N 6N5, Canada
| | - Dmitry V Veprintsev
- Laboratory for Biomolecular and Medical Technologies, Krasnoyarsk State Medical University, Krasnoyarsk 660022, Russia; Institute of Chemistry and Chemical Technology of the Siberian Branch of the Russian Academy of Science, Krasnoyarsk 660036, Russia
| | - Sergey S Bekuzarov
- Krasnoyarsk Regional Clinical Pathological Anatomical Bureau, Krasnoyarsk 660022, Russia
| | - Andrey K Kirichenko
- Laboratory for Biomolecular and Medical Technologies, Krasnoyarsk State Medical University, Krasnoyarsk 660022, Russia
| | - Ruslan A Zukov
- Laboratory for Biomolecular and Medical Technologies, Krasnoyarsk State Medical University, Krasnoyarsk 660022, Russia; Krasnoyarsk Regional Clinical Cancer Center, Krasnoyarsk 660022, Russia
| | - Marina M Petrova
- Laboratory for Biomolecular and Medical Technologies, Krasnoyarsk State Medical University, Krasnoyarsk 660022, Russia
| | - Andrey A Modestov
- Laboratory for Biomolecular and Medical Technologies, Krasnoyarsk State Medical University, Krasnoyarsk 660022, Russia; Krasnoyarsk Regional Clinical Cancer Center, Krasnoyarsk 660022, Russia
| | - Maxim V Berezovski
- Department of Chemistry and Biomolecular Sciences, University of Ottawa, Ottawa, ON K1N 6N5, Canada.
| | - Anna S Zamay
- Laboratory for Biomolecular and Medical Technologies, Krasnoyarsk State Medical University, Krasnoyarsk 660022, Russia; Institute of Chemistry and Chemical Technology of the Siberian Branch of the Russian Academy of Science, Krasnoyarsk 660036, Russia.
| |
Collapse
|